Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi Chugh

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
International Journal of Surgical Pathology|May 6, 2026
Retroperitoneal Schwannoma with a Novel <i>PRCC::TFE3</i> Fusion: Expanding the Spectrum of Schwannomas with a <i>TFE3</i> Gene RearrangementKyle D Perry, Rohit Mehra, Ann Leathersich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcomaFrancis P Worden, Jeremy M G Taylor, Janet S Biermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Journal of Surgical Oncology|March 3, 2022
Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomasBrooke C Bredbeck, Lia D Delaney, Varun G Kathawate, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Investigational New Drugs|January 28, 2020
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinomaDavid C Smith, Matthias Kroiss, Electron Kebebew, et al.
Seminars in Oncology|April 2, 2013
A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancerBudhi S Yadav, Anshuma Bansal, Suresh C Sharma, et al.
Genome Research|August 9, 2015
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencingMarcin Cieslik, Rashmi Chugh, Yi-Mi Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With SurvivalVadim S Koshkin, Vanessa Bolejack, Lawrence H Schwartz, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
International Journal of Surgical Pathology|May 6, 2026
Retroperitoneal Schwannoma with a Novel <i>PRCC::TFE3</i> Fusion: Expanding the Spectrum of Schwannomas with a <i>TFE3</i> Gene RearrangementKyle D Perry, Rohit Mehra, Ann Leathersich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcomaFrancis P Worden, Jeremy M G Taylor, Janet S Biermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Journal of Surgical Oncology|March 3, 2022
Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomasBrooke C Bredbeck, Lia D Delaney, Varun G Kathawate, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Investigational New Drugs|January 28, 2020
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinomaDavid C Smith, Matthias Kroiss, Electron Kebebew, et al.
Seminars in Oncology|April 2, 2013
A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancerBudhi S Yadav, Anshuma Bansal, Suresh C Sharma, et al.
Genome Research|August 9, 2015
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencingMarcin Cieslik, Rashmi Chugh, Yi-Mi Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With SurvivalVadim S Koshkin, Vanessa Bolejack, Lawrence H Schwartz, et al.
Pageof 13